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Abstract
The diagnosis of ADHD is often missed or misdiagnosed in people with Intellectual 
disability (ID). Despite a significant growth in literature on the diagnosis and treatment of 
ADHD in people without ID, there have been few studies on ADHD in people with ID. In this 
paper, we describe a group of adults with ID and ADHD open to a specialist community ID 
service. We examined the frequency and dose of antipsychotic use and considered whether 
ADHD medication is associated with a reduced use of psychotropic medication. The study 
found a high incidence of autism in people with ID and ADHD. Men with ID were given the 
diagnosis of ADHD more often compared to women with ID. Only 36% of people with ADHD 
and ID taking ADHD medication were on antipsychotic medications compared to 93% of 
people with ADHD and ID without ADHD medications. This generates several hypothesis 
such as whether antipsychotic medications are prescribed to control ADHD symptoms, 
whether use of ADHD medications can reduce the use of antipsychotic medications and/or 
whether antipsychotics are used to treat underlying psychiatric comorbidities in people with 
ADHD. Randomised controlled trials are needed to answer the question whether use of 
ADHD medication reduces use of antipsychotic medication in people with ID and ADHD. 
Further studies are also needed to explore reason for not using ADHD medication in certain 
patients with ADHD and ID and what treatment options are effective in treating psychiatric 
comorbidities in people with ADHD and ID. 
Accessible summary:































































● ADHD is often missed/underdiagnosed in people with ID compared to people without 
ID  
● Presence of ID, autism and challenging behaviour should raise the suspicion of 
ADHD as comorbid neurodevelopmental disorder
● Treatment of ADHD in people with ID may reduce the need for antipsychotic 
medications
Introduction
ADHD in Intellectual Disability
Intellectual Disability (ID) is defined as a neurodevelopmental disorder with onset during the 
developmental period with deficits in both intellectual and adaptive functioning in conceptual, 
social, and practical domains.  An overall prevalence of ID in the general population  was 
shown to be approximately 1.04% (Maulik, Mascarenhas, Mathers, Dua, & Saxena, 2011). 
The presence of one neurodevelopmental disorder (NDD) is known to increase the    co-
occurrence of other neurodevelopmental disorders (NDD). Therefore, it is important to 
consider other NDDs in people with intellectual disability. 
DSM V defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity 
that interferes with functioning or development (American Psychiatric Association, 2013). 
The diagnosis of ADHD in adults requires five or more symptoms to be present in 
hyperactivity/impulsivity and/or inattention domains and before the age of 12 years. The 
symptoms must be evident in two or more settings and associated with functional 
impairment. Although ADHD is commonly associated with children, studies have shown that 































































it persists during adolescence and adulthood in up to two-thirds of individuals and as full or 
partial persistence causing a functional impairment (Barkley, Fischer, Smallish, & Fletcher, 
2002; Lara et al., 2009). 
ADHD affects an estimated 3.4% of the adult population with worldwide estimates of 1.2-
7.3% (Fayyad et al., 2007, 2017). It is more prevalent in people with ID compared to the non-
ID population causing a significant functional impairment (Able, Johnston, Adler, & Swindle, 
2007). Several studies have shown a higher prevalence of ADHD in adults with ID ranging 
from 8.7% - 20.4% (Cantwell, 1996). A Swedish cohort study showed that “people with ID 
were at increased risk of ADHD compared to those without ID, and relatives of people with 
ID were at increased risk of ADHD compared with relatives of those without ID” (Faraone, 
Ghirardi, Kuja-Halkola, Lichtenstein, & Larsson, 2017). Shared genetic risk factors and a 
strong familial association may explain the comorbidity between ADHD and ID (Voigt, 
Barbaresi, Colligan, Weaver, & Katusic, 2006). Studies comparing people with ID to people 
without ID have shown that people with ID continue to have more symptoms of ADHD 
compared to people without ID from childhood to adulthood (Xenitidis, Paliokosta, Rose, 
Maltezos, & Bramham, 2010). Therefore, the evidence for assessing adults with ID for 
ADHD is compelling. Furthermore, it can be argued that diagnosing of ADHD in people with 
ID is even more important given it is the only diagnosis among NDDs such as Autism, ID, 
dyslexia and dyspraxia which has an evidence-base of effective pharmacological treatments. 
For example, a review concluded that psychostimulants (such as methylphenidate, 
dexamphetamine, mixed amphetamine salts and lisdexamfetamine) and non-
psychostimulants (such as atomoxetine) are significantly more efficacious than placebo for 































































treating ADHD (De Crescenzo, Cortese, Adamo, & Janiri, 2017). Authors also suggested 
that there was only preliminary evidence for the effectiveness of non-pharmacological 
treatments of ADHD in adults.
Under diagnosis of ADHD in ID
As highlighted by the World Health Organisation, people with learning disabilities experience 
various health inequalities; they have more chronic conditions than the general population, 
they develop chronic health conditions at a younger age, and also die sooner following 
diagnosis (World Health Organization [and] The World Bank, 2011). Moreover, it has been 
reported that there is an increase of ADHD symptoms in ID, which “could not be explained 
by inappropriate expectations or by confounding associations with other 
emotional/behavioural or cognitive problems” (Simonoff, Pickles, Wood, Gringras, & 
Chadwick, 2007) Despite this, ADHD is often considered as under-recognised in people with 
intellectual disability (Rose, Bramham, Young, Paliokostas, & Xenitidis, 2009) and 
recognising it can be challenging for multiple reasons (Perera & Courtenay, 2017). The core 
signs of ADHD of inattention and hyperactivity can also be manifestations of ID (Deb, 
Dhaliwal, & Roy, 2008). There is also the added factor of a higher prevalence rate of Autism 
in ID, which may make the diagnosis of ADHD even more complex. Problems associated 
with ADHD and their presentation are reported to vary depending on age (Montano, 2004; 
Rutter et al., 2011) where hyperactivity may present as extreme activity in a younger child 
compared to restlessness in an adult. Given that adults with ID have lower intellectual 
functioning compared to their chronological age, use of symptoms in adults without ID for 
diagnosing ADHD in ID population may not be accurate. The DSM V criteria for ADHD 































































include several symptoms, which can only be detected in people with verbal communication 
skills. A majority of people with severe ID have significant deficits in their expressive and 
comprehensive communication skills and therefore  these criteria may not be applicable 
(Perera, 2018). Having a pyschiatric co-morbidity can make the diagnosis of ADHD difficult ; 
two thirds of people with ADHD have at least one psychiatric comorbidity with an average 
number of co-morbidities of 2.4 per person (Piñeiro-Dieguez, Balanzá-Martínez, García-
García, Soler-López, & CAT Study Group, 2016). A high prevalence of mental illness in 
people with ID (Cooper, Smiley, Morrison, Williamson, & Allan, 2007) with a co-existent 
diagnosis ADHD can complicate the initial diagnosis and subsequent management of these 
underlying mental health issues. 
A recent review reported that antipsychotic medications are used in people with ID and 
challenging behaviour in the absence of a severe mental illness (Sheehan et al., 2015). In 
the ID/ADHD population we hypothesise that antipsychotics are used to manage ADHD 
symptoms, where ADHD medication should be the preferred treatment choice. 
Study aim
The study is part of a service evaluation project of people with ID and ADHD as a response 
to NHS England’s ‘stopping over medication of people with learning disability, autism or both 
with psychotropic medications’ (STOMP) campaign to stop the overuse of medications 
(NHS, 2018). We aimed to evaluate people with ID and a diagnosis of ADHD and treatment 
pathways in a specialist community ID service. We describe characteristics of the group of 































































adults with ID and ADHD; the frequency and dose of antipsychotic; and whether ADHD 
medication is associated with reduced psychotropic use. 
Methods
Study design and sample requirement
A psychiatry case register of people with intellectual disability and mental health difficulties 
open to the service were accessed for the period of 1 August 2017 to 1 September 2017.  
Inclusion criteria were as follows : 1) Formal diagnosis of intellectual disability  2) age greater 
than 18 years 3) Confirmed diagnosis of ADHD. The validity of the diagnoses of ADHD and 
ID was confirmed by inspecting the clinical records. Furthermore the diagnosis of ADHD was 
confirmed by a consultant psychiatrist in intellectual disabilities using clinical impression and 
DSM V criteria. Exclusion criteria included : 1) patients under the age of 18 years 2) unclear 
diagnosis of ADHD (insufficient records to make diagnosis/not formally diagnosed by a 
mental health professional/not present in adulthood/ insufficient evidence when correlated 
with clinical impression and DSM V) 3) borderline intellectual disability 4) Individuals no 
longer active on the case register at time of study (travel abroad/non compliance with 
service). 
Setting
The location of the study was in the London Borough of Haringey where over two thirds of 
the community are from ethnic minorities and over 100 languages are spoken. In the 
borough there are areas of great social deprivation. These socio demographic factors can 
add to the complexity of mental health diagnosis and treatment, however the diversity of this 































































study sample makes the findings more applicable to different patient groups given it 
represents a group of people with multiple genetic variability to social diversity.  The case 
series was conducted in Haringey Intellectual Disability services in London, a specialist 
integrated Intellectual Disability service providing health and social care inputs to adults with 
Intellectual disability living in the borough.
Data collection
Data was extracted from the records to include demographic data: age, gender, and severity 
of ID (mild, moderate, severe). Severity of ID was determined using intelligence quotient (IQ) 
in parallel with the level of adaptive and social functioning for that individual. Information on 
comorbid mental health problems (categorised in accordance with DSM V criteria) and 
current psychiatric medications (divided into antipsychotics, anxiolytics and hypnotics) were 
collected along with the use of stimulant and non-stimulant ADHD medication.    
The frequency and dosage of antipsychotic use in this group was also assessed. Dosage 
was given as a percentage of the maximum recommended dose for the antipsychotic in the 
British National Formulary (BNF) (Joint Formulary Committee, 2017). This is a reliable tool 
for standardizing antipsychotic doses in drug utilization research (Nosè et al., 2008; Sweileh 
et al., 2014). When two antipsychotics were used the individual percentages of the maximum 
dose were added to give a total percentage. Patients receiving a percentage of BNF 
maximum >100% were considered to have a high dose. The medications given and dosages 
prescribed vary throughout each individuals treatment pathway. The results described 
represent the medication profile at the time of data extraction (1 September 2017). 
































































Data were analysed using SPSS version 20.5. All variables were tested for normality using 
visual inspection and Shapiro-Wilk test. Differences between the groups were assessed with 
independent sample t-test. Pearson product-moment correlation coefficient was used to 
calculate correlation. An independent-sample t-test was conducted to compare antipsychotic 
dose in patients who were using ADHD medication compared to those who were not. The 
Shapiro-Wilk test with a Q-Q plot was used to assess for normality. A Pearson product-
moment correlation coefficient was also computed to assess the relationship between 
antipsychotic dose as a percentage of maximum BNF recommended dose compared to 
ADHD medication dose as a percentage of the maximum BNF recommended dose.
Results   
A total of 32 people with ID and ADHD were identified during the study period. Three were 
excluded as there was an unclear diagnosis as a result of insufficient information on ADHD 
status in adulthood. Data extraction and analysis were conducted on the remaining 29 cases 
who met inclusion criteria. Descriptive statistics are presented in Table 1. 
The diagnosis of ADHD was 6 times more prevalent in men than women in this group. More 
than half (55%) had severe intellectual disability. Downs syndrome was present in two cases 
and Smith Magenis syndrome in one.
Table 1: Case series characteristics (n = 29)





























































































Co-morbid diagnoses and psychotropic medication































































In this series 22 (76%) met the diagnostic criteria of autism spectrum disorder. Anxiety and 
mood disorders were the other two most common diagnoses with a prevalence of 21% and 
17% respectively. The prevalence of psychotic disorders and personality disorders was 3%. 
Comorbid psychiatric disorders did not correlate with using psychotropic medication. 79% of 
people with ADHD were using antipsychotic medication and 48% anti-anxiety medication. 
Fourteen people (48%) were using ADHD medication and of these 12 (86%) were using  
Atomoxetine and 2 (14%) Methylphenidate slow release preparations.
Antipsychotic use and ADHD
The antipsychotic profiles are summarised in tables 2 and 3. Twenty (69%) were using one 
antipsychotic drug and 3 (10%) were using two antipsychotics. Six (21%) were not using 
antipsychotic medication. None exceeded the maximum BNF recommended dose with 
majority (62%) on less than 25% of the recommended maximum dose. Fourteen were using 
ADHD medication, of which 5 (36%) were not using concomitant antipsychotic. Fifteen 
people with a diagnosis of ADHD were not using ADHD specific medication but were using 
antipsychotic medication of whom 3 (20%) were using two antipsychotics. There was no 
significant difference in antipsychotic dose in those using ADHD medication (M=27, SD=34) 
and those not (M=28, SD=23); t (27) = 0.145, p=0.886. There was no correlation between 
antipsychotic and ADHD medication dose, r- 0.201, n=29, p=0.295.
Table 2: Antipsychotic profile in all patients with ADHD (n = 29)
Number of antipsychotics Frequency (n=29)







































































































































Table 3: Antipsychotic profile of patients taking and not taking ADHD medication.
On ADHD 
Medication (n=14)












































































Mean % of maximum dose 27 28
Standard deviation of % of maximum dose 34 23
































































The service evaluation has raised important questions with regard to the diagnosis and 
treatment of ADHD in a group of people with ID and challenging behaviour.  We argue that 
there is not enough emphasis on ADHD as a neurodevelopmental disorder (NDD) in people 
with ID. Presence of one NDD is known to increase the risk of another NDD. Therefore, 
given ID as a NDDs, ADHD should be looked into in patients with ID. This is further 
supported by NICE (2018) Guidelines on ADHD recognising people with ID as a high risk 
group (NICE, 2018). Autism Spectrum Disorder in ID population is more often recognised 
and accepted compared to ADHD. Studies have shown that prevalence of ASD in people 
with ID is to be around 30 - 65% (Clark, Feehan, Tinline, & Vostanis, 1999; Ronald, 
Simonoff, Kuntsi, Asherson, & Plomin, 2008). The prevalence of autism in adults with ADHD 
and ID has not been reported in current literature. However in our series, the prevalence of 
autism in adults with ID and ADHD was 76%. The high prevalence reported may be a 
reflection of the increased risk of NDDs seen when one NDD is already present.   
ADHD is diagnosed and treated more often in males than in females with a ratio of 
approximately 3:1 (Cantwell, 1996). According to Arnett et al (2015), males showed more 
severe symptoms and significantly more variance compared to females (Arnett, Pennington, 
Willcutt, DeFries, & Olson, 2015) . We observed a higher male: female ratio of 6:1 in people 
with ID. A similar argument that men with ID show more severe symptoms and more 
variance which makes it easy to detect ADHD symptoms in men with ID may explain the 
reasons behind the high male to female ratio in ID in this study. 































































Diagnosis of ADHD can be considered challenging with increasing severity of ID. However, 
the majority (83%) in our case series had moderate to severe intellectual disability. This is in 
keeping with the current literature where the risk of ADHD increases with the severity of ID 
(Voigt et al., 2006). This shows that the diagnosis of ADHD can be considered irrespective of 
the severity of ID. Even though the study did not look into subtypes of ADHD , it is likely to 
that the diagnosis was made by the behaviour of the individual which meets the criteria for 
hyperactivity/impulsivity domain of DSM V criteria. 
This study raises various clinical conundrums and hypotheses. Challenging behaviour is 
common in people with ID. It is defined as “behaviour of an intensity, frequency, or duration 
that threatens the physical safety of the person or others or restricts access to community 
facilities” (Emerson, 2001). Symptoms of inattention, distractibility, impulsivity, and 
hyperactivity in ADHD can be perceived as challenging behaviour in people with ID. Studies 
have also shown that children with ID and ADHD are likely to have more conduct problems 
compared to children with ADHD without ID (Ahuja, Martin, Langley, & Thapar, 2013). 
Authors also reported that the presence of ADHD and ID combination increases the risk of 
Oppositional Defiant Disorders and Conduct Disorders compared to children with only ID or 
only ADHD. This shows the importance and complexities in diagnosing ADHD in people with 
ID along with the high rate of suspicion needed in children with ID for behavioural disorders. 
These may result in ADHD being missed in people with ID and challenging behaviour 
leading to inappropriate treatments such as use of antipsychotic medications.  This may be 
one of the explanations for the recent findings that 71% of patients with ID were using 
psychotropic drugs without a recorded severe mental illness in order to manage their ‘mood 































































dysregulation’  (Sheehan et al., 2015). These findings were also replicated in a study looking 
at prescribing in people with autism (Cvejic, Arnold, Foley, & Trollor, 2018). This is also 
paralleled by our series where 79% were using antipsychotic medication despite only 3% 
having a psychotic disorder. This raises the question why antipsychotic medications are 
used in this patient group off label. A case series of 61793 children reported that about 1 in 5 
children with a diagnosis of ADHD and long acting stimulant medications were also on a 
second generation antipsychotic (Kamble, Chen, Johnson, Bhatara, & Aparasu, 2015). 
Studies have also shown that the presence multiple psychiatric comorbidities as a single 
most predictor of polypharmacy and off label prescribing (Kearns & Hawley, 2014). This 
suggests that antipsychotic medications may be used for different purposes in patients with 
ID, ADHD and challenging behaviour. One hypothesis is that antipsychotic medications may 
be used to treat underlying comorbid psychiatric disorders such as anxiety disorders. 
There are several downfalls associated with the use of psychotropic drugs in people with ID 
without a severe mental illness. Although psychotropic drugs can reduce anxiety and 
improve sleeping patterns, there is no strong evidence base to support use of antipsychotic 
medications to treat the core symptoms of ADHD. Long-term antipsychotic use also has 
several side effects such as metabolic syndrome, weight gain, hyperprolactinaemia and 
sedation (McQuire, Hassiotis, Harrison, & Pilling, 2015). This study showed a clear 
difference in the use of antipsychotic medications between the two groups of people with ID 
and ADHD who take ADHD medication versus those not on ADHD medications. People who 
are not using ADHD medications were more likely to use one or more antipsychotics while 
those using ADHD medication used fewer antipsychotic medication. This raises the question 
whether ADHD medication use can reduce the use of antipsychotics. This association needs 































































to be explored through more robust research methodologies. However, this small case 
series suggests that the use of ADHD medications may be beneficial to reduce use of 
antipsychotics in people with ID. 
Stimulant (Methylphenidate) and non-stimulant (Atomoxetine) medication are the main 
pharmacological treatment options for ADHD both in the non-ID (Contini et al., 2013) and ID 
population (Ji & Findling, 2016). However, less than 50% in our series were using any form 
of ADHD medication. The reasons for this may include withdrawal as they progress into 
adulthood, lack of efficacy, intolerable side effects, family refusal, and/or clinician oversight. 
When comparing people who were using ADHD medication with those without there was no 
statistical difference in antipsychotic dose and no correlation between ADHD dose and 
antipsychotic dose. However, it is difficult to ascertain whether several confounders such as 
severity of ADHD, severity of ID, prescribing clinician, and co-morbid disorders that were not 
addressed could have an impact on psychotropic dosing. 
The effective diagnosis and treatment of ADHD can result in considerably reducing 
psychosocial burden. This is of particular importance, as there is a high functional and 
psychosocial impairment associated with adult ADHD including parental history of anxiety, 
dissatisfaction with love life, and consumption of tobacco (Moulin et al., 2018). Untreated 
ADHD could also contribute to functional impairment and occupational outcomes; for 
example, a cross-sectional study has demonstrated that “later age of first central stimulant 
treatment for ADHD and higher inattentiveness ratings were associated with lower level of 
employment” (Gjervan, Torgersen, Nordahl, & Rasmussen, 2012). Prompt treatment can 































































also affect long term outcomes, such as academic, antisocial behaviour, driving, non-
medicinal drug use/addictive behaviour, obesity, occupation, services use, self-esteem, and 
social function outcomes; it has been shown that ADHD treatment improved long-term 
outcomes compared with non-treatment, even though the outcomes did not reach normal 
levels (Shaw et al., 2012).
The combination of a high prevalence of ADHD and diagnostic overshadowing in the ID 
population warrants the development and routine use of a screening tool for ADHD tailored 
specifically towards the ID population. We also suggest that the high rate of co-morbid 
autism in ADHD/ID should prompt every clinician in considering autism spectrum disorder as 
an additional diagnosis. 
Limitations
There are several limitations in our study. As this is a local series with a sample size of 29 
these findings cannot be generalised to the ID/ADHD population as a whole. The series 
used a retrospective medical record review and therefore there may have been incomplete 
or missing data as well as difficulty in interpreting or verifying the documented information.
Future Research
Although ASD and ADHD are distinct disorders according to DSM-5, there is still a 
considerable genetic and clinical overlap between them (Rommelse, Franke, Geurts, 
Hartman, & Buitelaar, 2010; Rommelse, Geurts, Franke, Buitelaar, & Hartman, 2011). 
Mayes et al (2011) reported that children with ADHD did not present with many of the 































































symptoms on the Autism Screening Checklist and therefore children with autism can 
distinguished from children with ADHD (Mayes et al., 2011). However, children with Autism 
showed some of the symptoms such as inattention, impulsivity, and hyperactivity in maternal 
rating scales. Challenges in differentiating the two disorders in clinical practice may result in 
people with ADHD either under or over diagnosed in people with Autism. Further studies are 
needed to explore symptomatology which can be used to differentiate ADHD from Autism. 
Summary
ADHD is a neurodevelopmental disorder which is often neglected in people with ID.  There 
are diagnostic challenges related to ADHD in ID, however it is an important diagnosis to be 
considered given the strong evidence base and national guidelines when diagnosing and 
treating ADHD. Autism and ADHD appear to have highly comorbid in people with ID. This 
case series showed that only a smaller number of patients who take ADHD medications 
were on Antipsychotic medications compared to patients who were not taking ADHD 
medications. This raises clinical questions whether ADHD is treated using antipsychotics 
rather than evidence based pharmacological treatments as per national guidelines. More 
research is needed in people with ID and ADHD. 
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